HOME >> BIOLOGY >> NEWS
Study Ensures Effective Ways To Measure Macular Pigment Density

(FT. LAUDERDALE, Fla., May 9, 1999) - Dietary lutein and zeaxanthin are the major determinants to explain macular pigment optical density (MPOD), according to research presented today at the Association for Research in Vision and Ophthalmology 1999 annual meeting. The study was the largest ever conducted to examine the relationship between dietary, medical, physical and lifestyle factors, and macular pigment density, thought to be protective in age-related macular degeneration (AMD).

"Results confirmed and expanded upon what's already known about the determinants of macular pigment density. Dietary lutein and zeaxanthin explained the greatest amount of macular pigment density variance, followed by serum lutein levels," said Thomas Ciulla, M.D., Retinal Specialist, Indiana University School of Medicine and Ophthalmology Department in Indianapolis, Ind.

Ciulla and his colleagues examined the MPOD of a cross sectional population of 280 healthy men and women in Indianapolis. They determined that dietary lutein and zeaxanthin, serum lutein and eye color are the factors most strongly associated with macular pigment density. Ciulla cautions, however, that, taken together, these factors explained only 19.7 % variance in MPOD.

Lutein and zeaxanthin are concentrated in retinal macular pigment and accumulation is thought to be dependent on dietary intake. Macular pigment may filter blue light that damages photoreceptors and the retinal pigment epithelium. In addition, carotenoids may limit oxidant stress resulting from metabolism and light, acting as antioxidants.

In this study, serum concentrations for lutein, zeaxanthin and beta-carotene were measured by HPLC, and MPOD was measured by heterochromatic flicker photometry. Dietary patterns and demographic/medical characteristics were determined by questionnaire. This method of study was a non-invasive way to measure MPOD and also showed that MPOD can be rel
'"/>

Contact: Anne Tramer
atramer@selz.com
312-372-7090
Selz/Seabolt Communications
8-May-1999


Page: 1 2

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Ensures Effective Ways Measure Macular Pigment Density

(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalyst™ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Laboratory ... Top-Loading Balances and Analytical Balances to get best-performing ... line of weighing balances from the trusted brand ... Balances increase your efficiency by providing a ... of samples. Weighing modes include parts counting, percent ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: